It might be handy to license out one more indication to Acadia.
Neuren would get fantastic commercials for the milestones & royalties given how potentially lucrative it would be for Acadia. Potentially between Neuren and Acadia we could have 6 indication under staged development for phase3. A sign on fee of approx US$100M could go straight to increasing buyback to counter the depressed share price.
It wouldn’t particularly complicate takeover potential any more than is already in place however it may even provide a more compelling case at higher value.
Ann: NEU confirms primary endpoints for Phase 3 trial in PMS, page-110
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |